A Study of LY2951742 in the Prevention of Episodic Migraine (EVOLVE-1)
The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with episodic migraine.
The results of this study are not yet available.
Your participation could last up to 12 months and will include 14 visits to the study center
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have a diagnosis of episodic migraines, with a history of migraine headaches at least 1 year prior to screening for the study
Participant's migraines must have begun prior to age 50
Participant must not have a history of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine)